L5295
LY 320135
≥98% (HPLC)
別名:
4-[6-メトキシ-2-(4-メトキシフェニル)ベンゾフラン-3-カルボニル]ベンゾニトリル, LY320135, [6-メトキシ-2-(4-メトキシフェニル)ベンゾ[b]フラン-3-イル](4-シアノフェニル)メタノン
ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式（ヒル表記法）:
C24H17NO4
CAS番号:
分子量:
383.40
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
製品名
LY 320135, ≥98% (HPLC)
InChI
1S/C24H17NO4/c1-27-18-9-7-17(8-10-18)24-22(20-12-11-19(28-2)13-21(20)29-24)23(26)16-5-3-15(14-25)4-6-16/h3-13H,1-2H3
SMILES string
COc1ccc(cc1)-c2oc3cc(OC)ccc3c2C(=O)c4ccc(cc4)C#N
InChI key
RYNSGDFWBJWWSZ-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
orange
solubility
DMSO: ≥10 mg/mL
originator
Eli Lilly
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
LY320135は、CB1受容体のアンタゴニスト/インバースアゴニストであり(Ki = 141 nM)、CB2受容体(Ki > 10 μM)と比較してCB1に70倍を越える選択性を示しています。
LY320135は、CB1受容体のアンタゴニスト/インバースアゴニストであり(Ki = 141 nM)、CB2受容体(Ki > 10 μM)と比較してCB1に70倍を越える選択性を示しています。SR 141716AやAM 251とは構造的に異なっています。5-HT2(Ki = 6.4 μM)とムスカリン受容体(Ki = 2.1 μM)の両方に対して、弱い結合が認められています。
Features and Benefits
This compound is featured on the Cannabinoid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral
保管分類
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
K M Kampa-Schittenhelm et al.
EBioMedicine, 54, 102678-102678 (2020-04-10)
Overriding the differentiation blockage in acute myeloid leukemia (AML) is the most successful mode-of-action in leukemia therapy - now curing the vast majority of patients with acute promyelocytic leukemia (APL) using all-trans retinoic acid (ATRA)-based regimens. Similar approaches in other
Xinwen Zhang et al.
Neuropharmacology, 128, 269-281 (2017-10-25)
Monoacylglycerol lipase (MGL) hydrolyzes 2-arachidonoylglycerol to arachidonic acid and glycerol. Inhibition of MGL may attenuate neuroinflammation by enhancing endocannabinoid signaling and decreasing prostaglandin (PG) production. Almost half of HIV infected individuals are afflicted with HIV-associated neurocognitive disorder (HAND), a neuroinflammatory
Elham Khajehali et al.
Molecular pharmacology, 88(2), 368-379 (2015-06-06)
CB1 cannabinoid receptors (CB1Rs) are attractive therapeutic targets for numerous central nervous system disorders. However, clinical application of cannabinoid ligands has been hampered owing to their adverse on-target effects. Ligand-biased signaling from, and allosteric modulation of, CB1Rs offer pharmacological approaches
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）